Albany Molecular Research (AMRI) Tops Q4 EPS by 4c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMRI Announces Fourth Quarter and Full Year 2015 Results and Provides 2016 Outlook
February 17, 2016 7:30 AM ESTALBANY, N.Y., Feb. 17, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2015 and provided an outlook for 2016.
Fourth quarter total revenue of $126.4 million, up 46% from 2014; Full year total revenue of $402.4 million, up 45% Fourth quarter adjusted contract margins expand to 30%; Full year adjusted contract margins of 26% Fourth quarter adjusted EBITDA of $26.7 million; Full year adjusted EBITDA of $75.2 million Fourth quarter adjusted diluted EPS of $0.40; Full year adjusted diluted EPS of $0.96... More